Pleiotropic effects of herbs characterized with blood-activating and stasis-resolving functions on angiogenesis

Li Tao; Sheng Wang; Yang Zhao; Ai-yun Wang; Lei Zhang; Jun-shan Ruan; Fang-tian Fan; Yu-ping Liu; Yao Li; Zhi-qiang Yue; Wen-hui Qian; Wen-xing Chen; Yin Lu

doi:10.1007/s11655-015-2405-x

Your Location：

Home >

Browse articles >

Pleiotropic effects of herbs characterized with blood-activating and stasis-resolving functions on angiogenesis

Updated：2021-08-27

- Pleiotropic effects of herbs characterized with blood-activating and stasis-resolving functions on angiogenesis
- Chinese Journal of Integrative Medicine Vol. 22, Issue 10, Pages: 795-800(2016)
- Affiliations：
  
  1. Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine,Nanjing,China
  2. Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine,Nanjing,China
  3. Department of Pharmacy, Provincial Hospital Affiliated to Anhui Medical University,Hefei,China
  4. Fujian Provincial Hospital, Clinical College of Fujian Medical University,Fuzhou,China
  5. Department of Pharmacology, Hanlin College, Nanjing University of Chinese Medicine,Jiangsu Province,Taizhou,China
  6. Department of Pharmaceutics, Jinling Hospital, Nanjing University School of Medicine,Nanjing,China
- Author bio：
- Funds：
  
  Supported by the National Natural Science Foundation of China (Nos. 81173174, 81403260 and 81573859), China Post-doctoral Science Foundation (No. 2014M551639), Natural Science Foundation of Jiangsu Province (No. BK2012854), Postdoctoral Funding in Jiangsu Province (No. 1401138C), 2013 Program for Excellent Scientific and Technological Innovation Team of Jiangsu Higher Education (No. PPZY2015A070), the Priority Academic Program Development of Jiangsu Higher Education Institutions, and Jiangsu College Graduate Research and Innovation Projects (No. CXZZ13_0627)
- DOI：10.1007/s11655-015-2405-x
  CLC：
- Published：2016，
  
  Published Online：29 June 2016，
Scan for full text
Tao, L., Wang, S., Zhao, Y. et al. Pleiotropic effects of herbs characterized with blood-activating and stasis-resolving functions on angiogenesis., Chin. J. Integr. Med. 22, 795–800 (2016). https://doi.org/10.1007/s11655-015-2405-x

Li Tao, Sheng Wang, Yang Zhao, et al. Pleiotropic effects of herbs characterized with blood-activating and stasis-resolving functions on angiogenesis. [J]. Chinese Journal of Integrative Medicine 22(10):795-800(2016)
Tao, L., Wang, S., Zhao, Y. et al. Pleiotropic effects of herbs characterized with blood-activating and stasis-resolving functions on angiogenesis., Chin. J. Integr. Med. 22, 795–800 (2016). https://doi.org/10.1007/s11655-015-2405-x DOI：

Li Tao, Sheng Wang, Yang Zhao, et al. Pleiotropic effects of herbs characterized with blood-activating and stasis-resolving functions on angiogenesis. [J]. Chinese Journal of Integrative Medicine 22(10):795-800(2016) DOI： 10.1007/s11655-015-2405-x.

摘要

Accumulative evidences have underpinned the nature candidates from Chinese medicine (CM)

particularly CM served as blood activating and stasis resolving (BASR

Huoxue Huayu in Chinese) by targeting tumor-associated angiogenesis. However

recent experiment research on the therapeutic angiogenesis by BASR-CM attracts wide attention and discussion. This opinion review focused on the underlying link between two indications and anticipated that (1) BASR-CM might emphasize on a balanced multi-cytokines network interaction; (2) BASR-CM might address on the nature of diseases prior to differently affecting physiological and pathological angiogenesis; (3) BASR-CM might mainly act on perivascular cells

either promotes arteriogenesis by increasing arteriogenic factors in ischemic diseases

or simultaneously keep a quiescent vasculature to impede angiogenesis in tumor context.

Abstract

Accumulative evidences have underpinned the nature candidates from Chinese medicine (CM)

particularly CM served as blood activating and stasis resolving (BASR

Huoxue Huayu in Chinese) by targeting tumor-associated angiogenesis. However

either promotes arteriogenesis by increasing arteriogenic factors in ischemic diseases

or simultaneously keep a quiescent vasculature to impede angiogenesis in tumor context.

关键词

blood activating and stasis resolvingChinese Medicinepro-angiogenesisanti-angiogenesisphysiological angiogenesispathological angiogenesisarteriogenesis

Keywords

blood activating and stasis resolvingChinese Medicinepro-angiogenesisanti-angiogenesisphysiological angiogenesispathological angiogenesisarteriogenesis

references

Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182–1186.

Samant RS, Shevde LA. Recent advances in antiangiogenic therapy of cancer. Oncotarget 2011;2:122–134.

Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer 2010;102:S2–S9.

World Health Organization. WHO international standard terminologies on traditional medicine in the Western Pacific region. Geneva, Switzerland. World Health Organization 2007.

Chen ZX, Liu XQ, Gao WY, Liu CX. Studies on pharmacology, toxicology and pharmacokinetics of the chemical constituents in hemorrheologic agent. Asia J Pharmacokinet Pharmacodyn 2008;8:15–30.

Chang MY, ed. Applied classical and empirical anticancer prescriptions. Beijing: China Medical Science Press;1996.

Qian YF, Wang XJ. Effects of blood-activating and stasisresolving drugs on tumor formation and metastasis. J Tradit Chin Med 2009;29:301–310.

Lu X, Li B. Exploration of the effect and mechanism of activating blood circulation and stasis-removing therapy on tumor metastasis. Chin J Integr Med 2009;15:395–400.

Xi S, Zhang Q, Xie H, Liu L, Liu C, Gao X, et al. Effects of hydroxy safflor yellow A on blood vessel and mRNA expression with VEGF and bFGF of transplantation tumor with gastric adenocarcinoma cell line BGC-823 in nude mice. Chin J Chin Mater Med (Chin) 2009;34:605–610.

Zhang LJ, Chen L, Lu Y, Wu JM, Xu B, Sun ZG, et al. Danshensu has anti-tumor activity in B16F10 melanoma by inhibiting angiogenesis and tumor cell invasion. Eur J Pharmacol 2010;643:195–201.

Kim SA, Lee HJ, Ahn KS, Lee HJ, Lee EO, Ahn KS, et al. Paeonol exerts anti-angiogenic and anti-metastatic activities through downmodulation of Akt activation and inactivation of matrix metalloproteinases. Biol Pharm Bull 2009;32:1142–1147.

Bae MK, Kim SH, Jeong JW, Lee YM, Kim HS, Kim SR, et al. Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1. Oncol Rep 2006;15:1557–1562.

Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, et al. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res 2007;13:3423–3430.

Pang X, Yi Z, Zhang X, Sung B, Qu W, Lian X, et al. Acetyl- 11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res 2009;69:5893–5900.

Chen W, Lu Y, Wu J, Gao M, Wang A, Xu B. Beta-elemene inhibits melanoma growth and metastasis via suppressing vascular endothelial growth factor-mediated angiogenesis. Cancer Chemother Pharmacol 2012;67:799–808.

Chen YJ, Tsai YM, Kuo CD, Ku KL, Shie HS, Liao HF. Norcantharidin is a small-molecule synthetic compound with anti-angiogenesis effect. Life Sci 2009;85:642–651.

Chen L, Lu Y, Wu JM, Xu B, Zhang LJ, Gao M, et al. Ligustrazine inhibits B16F10 melanoma metastasis and suppresses angiogenesis induced by vascular endothelial growth factor. Biochem Biophys Res Commun 2009;86:374–379.

Yeh JC, Cindrova-Davies T, Belleri M, Morbidelli L, Miller N, Cho CW, et al. The natural compound n-butylidenephthalide derived from the volatile oil of Radix Angelica sinensis inhibits angiogenesis in vitro and in vivo. Angiogenesis 2011;14:187–197.

Zhang W, Lu Y, Xu B, Wu J, Zhang L, Gao M, et al. Acidic mucopolysaccharide from Holothuria leucospilota has antitumor effect by inhibiting angiogenesis and tumor cell invasion in vivo and in vivo. Cancer Biol Ther 2009;8:1489–1499.

Komi Y, Suzuki Y, Shimamura M, Kajimoto S, Nakajo S, Masuda M, et al. Mechanism of inhibition of tumor angiogenesis by beta-hydroxyisovalerylshikonin. Cancer Sci 2009;100:269–277.

Bian W, Chen F, Bai L, Zhang P, Qin W. Dihydrotanshinone inhibits angiogenesis both in vivo and in vivo. Acta Biochim Biophys Sin 2008;40:1–6.

Kwak HJ, Park MJ, Park CM, Moon SI, Yoo DH, Lee HC, et al. Emodin inhibits vascular endothelial growth factor-Ainduced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation. Int J Cancer 2006;118:2711–2720.

Liu J, Chen Z. Traditional Chinese medicine in the new century. Front Med 2011;5:111–114.

Wu ZG. Therapeutic angiogenesis: the combination point of Chinese and Western medicine in prevention and treatment of ischemic heart disease. Chin J Integr Med 2009;15:323–324.

Höckel M, Schlenger K, Doctrow S, Kissel T, Vaupel P. Therap eutic angiogenesis. Arch Surg 1993;128:423–439.

Li JH, Wu YL, Ye JH, Ning YG, Yu HY, Peng ZJ, et al. Effects of blood-activating and stasis-removing drugs combined with VEGF gene transfer on angiogenesis in ischemic necrosis of the femoral head. J Tradit Chin Med 2009;29:216–219.

Zhu HF, Wan D, Luo Y, Zhou JL, Chen L, Xu XY. Catalpol increases brain angiogenesis and up-regulates VEGF and EPO in the rat after permanent middle cerebral artery occlusion. Int J Biol Sci 2010;6:443–453.

Lin CM, Chiu JH, Wu IH, Wang BW, Pan CM, Chen YH. Ferulic acid augments angiogenesis via VEGF, PDGF and HIF-1 alpha. J Nutr Biochem 2010;21:c627–c633.

Nagy JA, Chang SH, Dvorak AM, Dvorak HF. Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer 2009;100:865–869.

Donnem T, Al-Saad S, Al-Shibli K, Delghandi MP, Persson M, Nilsen MN, et al. Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in nonsmall cell lung cancer. Clin Cancer Res 2007;13:6649–6657.

Bates DO. Vascular endothelial growth factors and vascular permeability. Cardiovasc Res 2010;87:262–271.

Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010;10:505–514.

Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004;4:437–447.

Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039–2049.

Messmer-Blust A, An X, Li J. Hypoxia-regulated angiogenic inhibitors. Trends Cardiovasc Med 2009;19:252–256.

Parekh HS, Liu G, Wei MQ. A new d awn for the use of traditional Chinese medicine in cancer therapy. Mol Cancer 2009;8:21.

Fukumura D, Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 2007;3:211–268.

Heil M, Eitenmüller I, Schmitz-Rixen T, Schaper W. Arteriogenesis versus angiogenesis: similarities and differences. J Cell Mol Med 2006;10:45–55.

Cao Y. Therapeutic angiogenesis for ischemic disorders: what is missing for clinical benefits? Discov Med 2010;9:179–184.

Wu P, Dugoua JJ, Eyawo O, Mills EJ. Traditional Chinese medicines in the treatment of hepatocellular cancers: a systematic review and meta-analysis. J Exp Clin Cancer Res 2009;28:112.

FULL TEXT LINK

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Inhibition of pathological angiogenesis of Chinese medicine against liver fibrosis

Future view and development of immunology: Exploring the immunology based on Chinese medicine and culture

Cost-effectiveness analysis of combined Chinese medicine and Western medicine for ischemic stroke patients

Objective tongue inspection on 142 liver cancer patients with damp-heat syndrome

Effect of Ermiao Recipe (二妙方) with medicinal guide Angelicae Pubescentis Radix on promoting the homing of bone marrow stem cells to treat cartilage damage in osteoarthritis rats

Related Author

No data

Related Institution

Shanghai University of Traditional Chinese Medicine

Georg-August-Universität Göttingen, Göttingen

The Key Laboratory of Geriatrics, Beijing Hospital and Beijing Institute of Geriatrics’ Ministry of Public Health

Medical Informatics Center, Peking University

Department of Hospital Management, Peking University Health Science Center, Peking University

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰